- Stocks
- Pharma & Healthcare
- Lactose India
Lactose India share price
NSE: LACTOSEPharma & HealthcareDrug Manufacturers - Specialty & Generic
Lactose India at a glance
With a market capitalisation of ₹132 Cr, it ranks 2506th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 8.8% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹46 Cr (+64.8% year on year) and net profit ₹2 Cr (+193.8%), on a standalone basis. Promoters held 53.65% of the company as of 30 Jun 2026; 26.07% of promoter shares were pledged.
Key numbers
- Market cap
- ₹132 CrRank 2506 on NSE
- Price to book
- 1.9×FY25
- EPS (TTM)
- ₹4.81to Q4 FY26
- ROE
- 8.8%FY25
- ROCE
- 14.7%FY25
- Debt to equity
- 0.96FY25
- Net profit margin
- 4.4%FY25
- Book value / share
- ₹46.66FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Lactose India quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹29 Cr | ₹30 Cr | ₹29 Cr | ₹28 Cr | ₹40 Cr | ₹41 Cr | ₹37 Cr | ₹46 Cr |
| Revenue YoY | +7.2% | +24.6% | −11.9% | −5.5% | +34.4% | +35.2% | +28.0% | +64.8% |
| Net profit | ₹2 Cr | ₹2 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr |
| Net profit YoY | +136.5% | +150.6% | −91.6% | −73.3% | −33.9% | +6.4% | +140.9% | +193.8% |
| Net margin | 7.7% | 6.7% | 0.8% | 2.3% | 3.8% | 5.2% | 1.4% | 4.1% |
| EPS | ₹1.80 | ₹1.61 | ₹0.17 | ₹0.51 | ₹1.19 | ₹1.71 | ₹0.42 | ₹1.49 |
Lactose India financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹40 Cr | ₹35 Cr | ₹46 Cr | ₹66 Cr | ₹114 Cr | ₹116 Cr |
| Operating profit | ₹0 Cr | −₹3 Cr | ₹3 Cr | ₹1 Cr | ₹10 Cr | ₹7 Cr |
| Net profit | ₹0 Cr | −₹2 Cr | ₹2 Cr | ₹1 Cr | ₹7 Cr | ₹5 Cr |
| EPS (₹) | ₹0.07 | −₹2.40 | ₹2.10 | ₹0.96 | ₹5.39 | ₹4.10 |
| Cash from operations | ₹8 Cr | ₹2 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | −₹0 Cr |
| Total debt | ₹34 Cr | ₹39 Cr | ₹34 Cr | ₹33 Cr | ₹24 Cr | ₹26 Cr |
| Shareholders' equity | ₹34 Cr | ₹35 Cr | ₹39 Cr | ₹41 Cr | ₹47 Cr | ₹59 Cr |
Lactose India shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% |
| Domestic institutions | 0.62% | 0.62% | 0.62% | 0.62% | 0.62% | 0.62% |
| Non-institutions | 45.74% | 45.74% | 45.74% | 45.74% | 45.74% | 45.74% |
| Promoter shares pledged | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% |
Lactose India vs peers
The listed Pharma & Healthcare companies nearest to Lactose India by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SMRUTHIORGSmruthi Organic | — | — | — | ₹135 Cr | — | — |
| LACTOSELactose India | — | — | — | ₹132 Cr | — | — |
| VALENCIAValencia Nutrit | — | — | — | ₹132 Cr | — | — |
| PARPar Drugs And Chemicals | ₹105.25 | −2.64% | +1.7% | ₹130 Cr | 9.9 | — |
| ASPIRAAspira Pathlab | — | — | — | ₹125 Cr | — | — |
| PARNAXLABParnax Lab | ₹108.95 | −3.52% | — | ₹125 Cr | 10.6 | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹57.16 | −5.99% | −20.6% | ₹123 Cr | — | — |
Ask anything about Lactose India
Pivot answers on the live chart with evidence you can check, and tests strategies against LACTOSE's own history. Try: “Why has LACTOSE moved over the last three months?” · “Backtest a 50-day moving-average crossover on LACTOSE over five years” · “Compare LACTOSE with SMRUTHIORG on margins and valuation”
Frequently asked questions about Lactose India
What is the market cap of Lactose India?
Lactose India's market capitalisation is ₹132 Cr (₹132 Cr) at the 19 Oct 2026 close, ranking 2506th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Lactose India?
Return on equity was 8.8% in FY25 and return on capital employed was 14.7% in FY25 (standalone figures).
Is Lactose India a debt-free company?
No. Lactose India's debt-to-equity ratio was 0.96 in FY25, with total debt of ₹26 Cr.
What were Lactose India's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Lactose India reported revenue of ₹46 Cr, +64.8% year on year, and net profit of ₹2 Cr, +193.8% year on year.
What is the shareholding pattern of Lactose India?
As of 30 Jun 2026: promoters 53.65%, domestic institutions 0.62%, non-institutions 45.74%. 26.07% of promoter shares were pledged.
Who are Lactose India's competitors?
The listed Pharma & Healthcare companies closest to Lactose India by market cap are Smruthi Organic, Valencia Nutrit, Par Drugs And Chemicals, Aspira Pathlab, Parnax Lab and Krebs Biochemicals and Industries.
Is Lactose India a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Lactose India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LACTOSE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with L · all NSE stocks · this page as text